secwatch.observer — SEC 8-K summary
======================================

Issuer:     IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
CIK:        0001425205
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0001104659-23-057722
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iovance Q1 net loss $107.4M, cash $632.7M; BLA submitted for lifileucel
-----------------------------------------------------------------------

- Q1 net loss $107.4M ($0.50 per share) vs loss of $91.6M ($0.58) in Q1 2022.
- Cash $632.7M as of Mar 31, 2023, incl $260.1M from ATM facility; expected to fund into H2 2024.
- Completed rolling BLA submission for lifileucel in post-anti-PD-1 advanced melanoma in March 2023.
- Plans to acquire Proleukin; closing expected Q2 2023.
- Commercial launch preparations for lifileucel on track for 2023; iCTC capacity for 2,000+ patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1425205/000110465923057722/0001104659-23-057722-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1425205/000110465923057722/tm2315161d1_8kseq1.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-057722

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer